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We conducted a nationwide, full-population based investigation to evaluate the comparative
effectiveness of all marketed second generation antipsychotic drugs (SGA) prescribed for outpatients
with the diagnosis of schizophrenia in Hungary. Using the national central register, our observational
follow-up study included all patients with schizophrenia or related disorder between 01/01/2006 and
30/06/2008. The study cohort comprised 9567 patients who started new SGA during the inclusion
period (01/07/2007–30/06/2008). All-cause medication discontinuation of 8 SGAs (1 depot and 7 oral
formulations) marketed during the inclusion period, and the time to all-cause discontinuation were
the main outcomes. Statistical models included the Kaplan–Meier and the Cox proportional hazards
models with propensity score adjustment. Patients treated with a depot formulation risperidone had
the longest time to discontinuation with a median of 215 days (95%CI:181–242 days), which was
statistically signiﬁcantly different compared to patients treated with the rest of the medications:
olanzapine (136 days, 95%CI:121–153 days), aripiprazole (102 days, 95%CI:81–126 days), ziprasidone
(93 days, 95%CI:82–119 days), quetiapine (89 days, 95%CI:81–100 days), clozapine (76 days,
95%CI:54–92 days), amisulpride (73 days, 95%CI:62–85 days), and risperidone (55 days, 95%CI: 41–63
days). Our results in Hungary are partly similar to those of a recent register-based study in FinlandElsevier B.V. and ECNP. All rights reserved.
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I. Bitter et al.1384with patients who were discharged from their ﬁrst hospitalization for schizophrenia (Tiihonen et al.,
2006, 2011); namely the median times to all-cause medication discontinuation were o120 days for
the majority of the oral SGA. In terms of medication differences, our data support the superior
effectiveness of the depot formulation regarding all-cause discontinuation, followed by olanzapine at
the efﬁcacy rank order.
& 2013 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Oral formulations of second generation antipsychotic drugs
(SGA) have been introduced in the last two decades and
recently they were followed by long-acting formulations
(Kane et al., 2003; Lauriello et al., 2008). Several clinical
trials addressed the effectiveness of SGA as compared to the
ﬁrst generation antipsychotic drugs (FGA) (Lieberman et al.,
2005; Kahn et al., 2008). Additional studies focused on the
effectiveness of antipsychotic drugs under real-life condi-
tions (Kelin et al., 2011; Swartz et al., 2005). Some of these
studies, especially by Medicare/Medicaid groups in the U.S.
(Chen et al., 2008; Zhao et al., 2004), aimed to mimic
clinical studies in order to examine the superiority of SGA
over FGA and to investigate whether there is a difference in
effectiveness among the various SGA.
There is a scarcity of data on the comparative effectiveness
of depot antipsychotics. Leucht et al. (2011) could identify only
10 randomized studies that compared intramuscular depot with
oral formulations of antipsychotic drugs in people with schizo-
phrenia or related disorders in long-term studies deﬁned as
1 year or longer (Leucht et al., 2011). A more recent meta-
analysis including 21 randomized controlled studies (RCTs)
found that oral and depot formulations of antipsychotics were
similar for relapse prevention and the authors emphasized, that
RCTs are less representative of real-world patients than
naturalistic studies and called for further studies with ‘‘real
word’’ patients (Kishimoto et al., 2013).
Hungary is one of the few countries where the access to
health care data is guaranteed by law. Its health care
system is predominantly state owned: the National Health
Insurance Fund (NHIF) covers 100% of the population of 10
million inhabitants. NHIF provides de-identiﬁed patient data
on healthcare services and major medical outcomes.
Through a collaboration of Academia (Department of
Psychiatry and Psychotherapy, Semmelweis University), the
payer (NHIF), the pharmaceutical industry (Janssen-Cilag
Hungary and EMEA) and an independent consulting company
(Healthware Ltd) we conducted a study to investigate the
population of patients with schizophrenia in Hungary.
The analyses were conducted by an independent biostatisti-
cian (LK) who worked for the government agency (the payer,
NHIF). Our aim was to evaluate the comparative effectiveness
of the SGA marketed in Hungary in a deﬁned study period.2. Experimental procedures
2.1. Data, study design and patient population
This was a parallel-group, register-based observational follow-up
study of all patients in Hungary who(1) had at least one record of schizophrenia diagnosis (F20.0-F20.9
according to the International Classiﬁcation of Diseases, 10th
revision ICD-10) (World Health Organization, 1992) between 01/
01/2006 and 30/06/2008 (patient pool), and(2) had been initiated on a new antipsychotic drug as monotherapy
during the inclusion period of 01/07/2007 and 30/06/2008
(study population).A new antipsychotic drug was deﬁned as no prescription of the
same compound during the previous 6 months.
No further criteria were applied; the broad inclusion criteria
aimed to increase the generalizability of the ﬁndings to treatment
in usual-care settings using the register of the NHIF. This register
allows identifying all patients in Hungary with a record of any
reimbursed drug prescription since 1998. Information on patient-
related events, including therapy discontinuation, switch to a new
medication, hospitalization, co-morbidity and mortality are
recorded in the system both for inpatient and outpatient care.2.2. Study periods and treatment groups
We studied the relative effectiveness of widely used oral and depot
SGAs prescribed as monotherapy for outpatients with the schizo-
phrenia diagnosis. In the nation-wide cohort of patients with
schizophrenia in Hungary that we investigated, second generation
antipsychotics constitute the majority of the total antipsychotic
market (market share=63%). The minority share of the market
(37%) by the ﬁrst generation antipsychotics (FGA) was distributed
among considerably more medications than in the case of SGA,
which would have made the comparison of the individual FGAs
infeasible.
Monotherapy was deﬁned as only one antipsychotic prescription
at the day of therapy initiation, and no further prescription during
the next 30 days (except for temporary oral supplementation at the
initiation of Risperidone Long-Acting Injectable [RLAI] or dose
increase). Only those SGAs were excluded from the study that were
either not available during the whole inclusion period (paliper-
idone), or were used by only a small number of patients (sertindole
and zotepine, no25). The top part of Fig. 1 displays the study
periods, whereas the bottom part (in red) shows the inclusion
process and study procedures for a particular patient.
During the 1-year inclusion period, all patients were included
who (a) started a new monotherapy (Day 1 in the inclusion period)
between 01/07/2007 and 30/06/2008 and (b) had no other FGA or
SGA prescription for the subsequent 30 days. In order to be
classiﬁed as new monotherapy, no prior prescription of the same
compound was allowed during the previous 6 months, which was
conﬁrmed in the retrospective period (Fig. 1). All included patients
were observed for 365 days from Day 1 (observation period).
The investigation had eight parallel treatment groups focusing on
the eight most frequently used SGA in the country, conﬁrmed by
sales records for the years 2008 and 2009. These medications
included the following seven oral SGA: amisulpride (AMIS), aripi-
prazole (ARIP), clozapine (CLOZ), olanzapine (OLAN), quetiapine
(QUET), risperidone (RISP), and ziprasidone (ZIPR), and one
30/06/2009
Retrospective period
01/07/2007 30/06/2008
Inclusion period Observation period
01/10/2008 01/01/2009 01/04/2009
Establish new monotherapy start
& start of observation with new
monotherapy medication
(Day 1, no other FGA or SGA
prescription for 30 days)
Length of observation: 365 daysConfirm no prior (6 month
period) presciption of
new monotherapy
medication identified
during  the inclusion 
30 days
01/01/2007
365 days to include all patients  who started a
new  SGA monotherapy during this period
Patient inclusion
can start at any point in the inclusion  period
from the point of inclusion
can start at any point in the inclusion  period, and
goes back in time from the point  of  inclusion
Fig. 1 Study periods and procedures. (For interpretation of the references to color in this ﬁgure, the reader is referred to the web
version of this article.)
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treatment group was decided after conﬁrming eligibility, as
discussed above.
2.3. Statistical analysis
2.3.1. Pre-processing of records of medication purchase
The centralized NHIF register in Hungary indicates whether a
patient purchased drugs with reimbursement from a pharmacy.
Antipsychotic drugs for schizophrenia patients receive practically
full reimbursement (patients pay a ﬁxed fee of ca. 1 Euro/box of
reimbursed medications). All outpatient disposals of antipsychotic
medications are documented, ﬁled and entered into an NHIF
database. The data records contain details of the product (strength,
dosage form, and formulation), and the disposal. We classiﬁed drugs
according to the Anatomic Therapeutic Chemical classiﬁcation
system (Norwegian Institute of Public Health, 2012). Using this
information, we assigned patients who took only one antipsychotic
drug to a respective monotherapy treatment group; in case of RLAI,
oral supplementation with risperidone was not considered a second
medication. Monotherapy was deﬁned as only one antipsychotic
prescription at Day 1 (therapy initiation), with no further prescrip-
tion of other FGA or SGA during the next 30 days. Except for
clozapine, the median daily doses of all medications were in close
agreement with the WHO DDD (amisulprid=400 mg, aripiprazole=15
mg, olanzapine=10 mg, quetiapine=400 mg, risperidone=5 mg,
risperidone-depot=2.7 mg, and ziprasidone=80 mg). Thus, similar
to Tiihonen et al. (2011), with the exception of clozapine, we
adopted the WHO DDD to calculate the duration of a prescription
using drug purchasing data. For clozapine, the median dose
(107 mg/day) was substantially lower than the DDD (300 mg/day);
thus, we adopted this value for the analyses.
2.3.2. Outcome variables
The primary outcome was the risk of all-cause discontinuation of
the antipsychotic medication used for the assignment to a given
treatment group. All-cause discontinuation during the ﬁrst year
after medication initiation was deﬁned with the following events
(Lieberman et al., 2005; Kahn et al., 2008): a 460 days gap in the
initial monotherapy medication; switch to new medication (inconjunction with a discontinuation of the initial medication); and
all-cause mortality. The 60-day threshold for gap duration was
chosen because we wanted to capture the majority of patients who
continue on their initial medication after pausing therapy.
The duration of gap was determined for each prescription: it was
deﬁned as the number of days elapsed with no subsequent record of
prescription of the same medication from the end of the prescrip-
tion duration of the initial medication. For all medications except
clozapine, the duration of prescription was calculated as the total
amount of the prescribed medication (mg) divided by deﬁned daily
dose. For clozapine, the median observed daily dosage (107 mg/
day) was used.
In case of discontinuation (460 days gap), we estimated the
date of discontinuation as 14 days after the day of last prescription
for the given drug. This was due to the fact that the last day of
treatment in register-based cannot be deﬁned precisely by the
database. The 14-day interval after the last prescription was
adopted because in case of RLAI this time period is deﬁned by
usage according to SMPC, and we wanted to apply a uniform
criterion across depot and oral medications.
For the analysis of all-cause discontinuation, patients’ follow-up
ended when their initial treatment changed for any reason,
including death, or the end of the study period, whichever occurred
ﬁrst. Patients without a clinical event of interest (i.e., discontinua-
tion of initial antipsychotic, switch to another drug or death) at the
end of the observation period (365 days after Day 1) were
considered censored.
For all non-censored observations, time to discontinuation was
deﬁned as the time elapsed from the ﬁrst prescription in the
inclusion period to the date of the ﬁrst of the aforementioned
qualifying events (i.e., the last day of prescription duration +14
days for discontinuations; and the date of dispensation of the new
medication for switches).
Secondary outcomes were hospitalization—deﬁned as admission
to active psychiatric ward—and documented suicide attempt.
2.3.3. Analysis models
The analyses focused on pairwise comparisons among the eight
selected antipsychotic medications based on the intention-to-treat
(ITT) principle. Thus, if a patient was initiated on concomitant
antipsychotic medication after the index date, the initial treatment
I. Bitter et al.1386assignment was retained, i.e., s/he was included in the original
(‘assigned’) treatment cohort in the analyses.
Time to all-cause medication discontinuation was analyzed by
Kaplan–Meier survival analysis and the Cox proportional-hazards
regression model. We report the resulting hazard ratios with 95%
conﬁdence intervals (CIs). Pairwise analyses of individual contrasts
between all included study medications constituted the main
interest.
To control for potential selection bias, for the Cox regression
propensity score-based adjustment was used based on the following
parameters: gender, age at baseline, number and length of previous
hospitalizations and medication compliance. Medication compli-
ance was assessed on the basis of medication disposition rather than
on the actual consumption. It was indexed by the prescription-
based estimated proportion (%) of days when an AP medication was
taken as compared to total the length of the baseline period (i.e.,
6 month prior to the inclusion period). These variables used for the
propensity score-based adjustment were previously associated with
nonadherence in the treatment of schizophrenia (Sellwood and
Tarrier, 1994; Klingberg et al., 2008; Lieberman et al., 2005; Kahn
et al., 2008). We estimated the conditional probability of receiving
a certain drug using a multinomial log–linear model. From these
probabilities, propensity scores were estimated. Results reported in
this publication represent ‘adjusted estimates’, i.e., the propensity
score and covariate based estimates of risk (hazard) ratios.
We conducted sensitivity analyses to assess the robustness of our
results, including an extension of the medication gap period from 60
to 90 days. Signiﬁcance level was set at a=0.05 (two-tailed). We
used the Hochberg procedure for statistical adjustment to avoid
inﬂation of Type 1 error due to multiple comparisons.51 842 pa
Total patient 
in/outpa
9 567 pat
involve
920 assigned to 
amisulpride
601 assigned to
aripiprazole
790 assigned to
clozapine
1 633 assigned to
olanzapine
1
742 (80.7%)
Discontinuation
278 Hospitalization
28 suicide attempts
29 Death
431 (71.7%)
Discontinuation
179 Hospitalization
13 suicide attempts
14 Death
573 (72.5%)
Discontinuation
149 Hospitalization
9 suicide attempts
20 Death
1118 (68.5%)
Discontinuation
541 Hospitalization
57 suicide attempts
49 Death
1
D
5
45063 pa
Prescripti
2007 H2-20
39 398 pa
Atypical Pres
2007 H2-20
Fig. 2 Patient eligibility and ﬂow in the study. Notes for Figure 2
and deaths of any cause were determined based on the intention
membership assignment (raw number of observed events in the ITTAll statistical analyses were run on the servers of NHIF and only
the outputs were eligible for further investigations, without any
access to patient-level data outside of NHIF. All analyses were
carried out using the R-software and by the Statistical Analysis
System (SAS) version 9.2 (SAS Institute, Cary, NC).3. Results
3.1. Patient eligibility and ﬂow in the study
As shown in Fig. 2, the patient pool consisted of 51,842
patients who received the diagnosis of schizophrenia (i.e.,
code F20.0-F.20.9 according to ICD-10) as either an in-, or
out-patient at least once during the period of 01/01/2006–
30/06/2008. A total of 45,063 of these patients received a
prescription for (any) antipsychotic drug, reimbursed by
NHIF between 01/07/2007 and 30/06/2008. Of these,
39,398 patients received SGA prescription. Among these
patients, 9567 were initiated on new monotherapy with any
of the eight medications, and thus constituted the study
population. As shown by the respective sample sizes in
Fig. 2, the most frequently prescribed initial monotherapy
drug (i.e., index purchase) in the sample was risperidone,
followed by olanzapine, quetiapine, RLAI, amisulpride,
clozapine, aripiprazole and ziprasidone.tients
pool (F20
tient)
ients
d
 587 assigned to
quetiapine
2 480 assigned to
risperidone
1 095 assigned to
RLAI
461 assigned to
ziprasidone
209 (76.2%)
iscontinuation
27 Hospitalization
49 suicide attempts
80 Death
2111 (85.1%)
Discontinuation
659 Hospitalization
51 suicide attempts
133 Death
667 (60.9%)
Discontinuation
440 Hospitalization
26 suicide attempts
37 Death
348 (75.5%)
Discontinuation
167 Hospitalization
17 suicide attempts
12 Death
tients
on in
08 H1
tients 
cription in
08 H1
: All clinical events including hospitalizations, suicide attempts
-to-treat principle, i.e., based on the initial treatment group
sample).
1387Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia3.2. Demographic and basic descriptive
characteristics
Demographic and descriptive data on the study population
as a whole and broken down by treatment group are
presented in Table 1.
The eight treatment groups were relatively well balanced
in age (o8 years difference in mean age across groups),
gender (r12% variation in gender ratio), and rate of suicide
attempts (r2% variation across groups). The groups, how-
ever, signiﬁcantly differed (po0.05) in the proportion of
prior hospitalizations: 58% of all patients on RLAI were
hospitalized during the 6 month period preceding the
inclusion in the study whereas in the other groups the
hospitalization rate during the prior 6 months ranged from
23% (clozapine) to 44% (olanzapine).3.3. Patient disposition
The percentage of patients who discontinued the initial
therapy is depicted in the last row of Fig. 2. Only a small
proportion of patients completed the study period withoutFig. 3 Kaplan–Meier estimates for time-to-discon
Table 1 Demographic and basic descriptive data of the study
Treatment
group
N
(total /group)
Mean
age (year)
Women,
N (%)
Amisulpride 920 47.01 569 (62%)
Aripiprazole 601 43.26 375 (62%)
Clozapine 790 48.31 420 (53%)
Olanzapine 1633 46.27 958 (59%)
Quetiapine 1587 49.72 1038 (65%)
Risperidone 2480 50.63 1484 (60%)
RLAI 1095 45.62 618 (56%)
Ziprasidone 461 45.65 300 (65%)
aNumber of patients hospitalized in psychiatric ward in the 6 mon
bNumber of patients with suicide attempts in the 6 month perioddiscontinuing the originally assigned (index) medication.
The lowest proportion of discontinuation was in the RLAI
group (60.9%), followed by olanzapine (68.5%), aripiprazole
(71.7%) clozapine (72.5%), ziprasidone (75.5%), quetiapine
(76.2%), amisulpride (80.7%) and oral risperidone (85.1%).
Further details on patient disposition are provided in the
Web Extra Material.3.4. Relative effectiveness: all-cause
discontinuation of initial (index) treatment
Fig. 3 shows the results of the non-parametric Kaplan–Meier
survival analysis of time to discontinuation for any reason,
excluding deaths, of the eight antipsychotics in the ﬁrst
year after medication initiation.
The left panel of Fig. 3 shows time to discontinuation KM
curves for each of the eight antipsychotic treatments while
the right panel depicts the point estimates and 95%
conﬁdence intervals (CI) of median time to discontinuation
based on the eight KM curves.
Compared with patients on oral antipsychotics, RLAI treated
patients had a longer time to discontinuation with a mediantinuation for any reason, based on raw data.
population.
Hospitalizationsa, 6
months prior baseline N (%)
Suicide attemptsb, 6
months prior baseline N (%)
330 (36%) 26 (3%)
221 (37%) 13 (2%)
184 (23%) 9 (1%)
715 (44%) 45 (3%)
631 (40%) 34 (2%)
826 (33%) 40 (2%)
640 (58%) 28 (3%)
156 (34%) 11 (2%)
th period prior baseline.
prior baseline.
I. Bitter et al.1388value of 215 days (95%CI:181–242 days), which was statistically
signiﬁcantly different compared to patients treated with the
rest of the medications: olanzapine (136 days, 95%CI:121–153
days), aripiprazole (102 days, 95%CI:81–126 days), ziprasidone
(93 days, 95%CI:82–119 days), quetiapine (89 days, 95%CI:81–
100 days), clozapine (76 days, 95%CI:54–92 days), amisulpride
(73 days, 95%CI:62–85 days), and risperidone (55 days, 95%CI:
41–63 days).
Table 2 shows the adjusted hazard ratios for all-cause
treatment discontinuation of the eight antipsychotic treat-
ments. Treatment with RLAI was associated with signiﬁcantly
lower risk of all-cause discontinuation than treatment with the
other medications, whereas olanzapine was also superior to the
remaining six medications. Four of the oral medications (ARIP,
CLOZ, QUET, ZIPR) did not signiﬁcantly differ from each other in
terms of all-cause discontinuations. Additionally, the hazardTable 2 Adjusted hazard ratios of all-cause discontinuatio
treatments, adjusted for differences in baseline characteristi
regression).
Adjusted hazard
ratio (95% CL) p-
value
AMIS
(n=920)
ARIP
(n=601)
CLOZ
(n=790)
OLAN
(n=1
AMIS – 1.18 1.07 1.38
(n=920) (1.041.34) (0.931.24) (1.25
p=0.117 p=0.92 p=0.
ARIP 0.85 – 0.99 1.19
(n=601) (0.750.98) (0.841.17) (1.06
p=0.117 p=0.92 p=0.
CLOZ 0.93 1.01 – 1.17
(n=790) (0.801.08) (0.861.18) (1.02
p=0.92 p=0.92 p=0.
OLAN 0.72 0.84 0.86 –
(n=1633) (0.650.80) (0.750.94) (0.750.98)
p=0.0019 p=0.045 p=0.22
QUET 0.90 1.08 0.98 1.29
(n=1587) (0.820.99) (0.961.21) (0.861.12) (1.18
p=0.37 p=0.92 p=0.92 p=0.
RISP 1.06 1.26 1.19 1.55
(n=2480) (0.961.18) (1.121.43) (1.041.36) (1.42
p=0.92 p=0.0036 p=0.12 p=0.
RLAI 0.60 0.71 0.73 0.86
(n=1095) (0.530.67) (0.620.82) (0.630.85) (0.77
p=0.0019 p=0.0019 p=0.0019 p=0.
ZIPR 0.96 1.13 1.08 1.35
(n=461) (0.841.10) (0.981.31) (0.901.30) (1.18
p=0.92 p=0.92 p=0.92 p=0.
Cell layout:
 Adjusted hazard ratio (HR), i.e., risk of event in the group
 (i.e., a value of o1 indicates a risk reduction for group in
 Upper and Lower 95% conﬁdence limits of HR.
 adjusted p-value in pairwise comparisons after correction
nAdjusted hazard ratio indicates that the null-hypothesis of no grou
1, after Hochberg correction based on the entire set of pairwise comrate for discontinuation was signiﬁcantly lower for aripiprazole
as compared to amisulpride, and for aripiprazole, quetiapine
and ziprasidone as compared to risperidone.
For the primary analyses, discontinuation was deﬁned by the
ﬁrst medication gap with460 days after medication initiation
(see Section 2). To examine whether this choice had impacted
the group comparison results, we conducted sensitivity ana-
lyses extending the gap period to 90 days. The relative
effectiveness of medications remained generally similar with
the adoption of the alternative criterion for the gap.
We also investigated the proportion of patients who
received polypharmacy, deﬁned as at least one prescription
of another SGA before medication discontinuation. We
found that the proportion of patients across the majority
of study groups was around 25%, and varied within relatively
narrow (710%) range for all treatments.ns by treatment: pairwise comparisons among individual
cs of the patients (propensity score included in the Cox
633)
QUET
(n=1587)
RISP
(n=2480)
RLAI
(n=1095)
ZIPR
(n=461)
1.11 0.94 1.68 1.04
1.53) (1.011.22) (0.851.04) (1.481.90) (0.911.20)
0019 p=0.37 p=0.92 p=0.0019 p=0.92
0.93 0.79 1.40 0.89
1.34) (0.831.04) (0.700.89) (1.211.62) (0.771.03)
045 p=0.92 p=0.0036 p=0.0019 p=0.92
1.02 0.84 1.37 0.93
1.33) (0.891.16) (0.740.96) (1.171.60) (0.771.11)
22 p=0.92 p=0.12 p=0.0019 p=0.92
0.78 0.65 1.16 0.74
(0.720.85) (0.590.70) (1.041.30) (0.650.84)
p=0.0019 p=0.0019 p=0.0096 p=0.0019
– 0.86 1.58 0.96
1.40) (0.790.93) (1.411.77) (0.851.09)
0019 p=0.0051 p=0.0019 p=0.92
1.16 – 1.88 1.20
1.68) (1.071.26) (1.672.10) (1.051.37)
0019 p=0.0051 p=0.0019 p=0.084
0.63 0.53 – 0.63
0.96) (0.570.71) (0.480.60) (0.540.75)
0096 p=0.0019 p=0.0019 p=0.0019
1.04 0.83 1.58 –
1.53) (0.921.18) (0.730.95) (1.341.86)
0019 p=0.92 p=0.084 p=0.0019
depicted in row as compared to group depicted in column
row).
for multiple testing based on the Hocherg procedure.
p difference is rejected (i.e., HR-value signiﬁcantly differs from
parisons presented in Table 2).
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Physicians may consider a number of variables before
choosing an antipsychotic for their patient with the diag-
nosis of schizophrenia, e.g. the efﬁcacy, tolerability, safety
and price of the drugs, and patient preference. Efﬁcacy of
antipsychotics for obtaining marketing authorization by
regulatory agencies has to be tested against placebo which
does not provide the clinician with guidance for selecting
the ‘‘right drug for the right patient’’. Direct comparisons
between antipsychotics, especially between more than two
antipsychotics are scarce or not existing.
Large observational studies are helpful; however, they also
have limitations regarding generalizability, due to the unba-
lanced number of patients with different antipsychotics and
large regional variability in the risk of treatment disconti-
nuation (e.g. Bitter et al., 2008) or the limited, number of
antipsychotics in the study (e.g. Thomas et al., 2010). In
general, the observational (non-randomized) design limits
internal validity, and thereby endangers external validity.
Analyses of prescription databases, which contain data from
real-world practice settings with a large sample size, may be
biased since they focused on speciﬁc populations (e.g.,
Medicaid or Medicare patients in the U.S.; Chen et al.
(2008)). Moreover, when several forms of coverage are avail-
able individual prescription databases can be incomplete since
patients may receive care from multiple sources; furthermore,
the results can be confounded since patients may not maintain
continuous eligibility within one system.
Nationwide register-based studies may overcome some of
the pitfalls of registration and observational studies and of
the analyses of insurance databases. The nationwide
register-based study conducted in Finland by Tiihonen
et al. (2006) used an observational follow-up design and
investigated discontinuation due to any cause as a principal
measure of effectiveness. The Finnish study focused on
the relative effectiveness of ﬁrst and second generation
antipsychotics in a nationwide patient cohort in community
care after ﬁrst hospitalization due to schizophrenia or
schizoaffective disorder. Additionally, in a further analysis
of the Finnish nationwide register data Tiihonen et al.
(2011) compared oral and depot neuroleptics in terms of
all-cause discontinuation and rehospitalization after dis-
charge from ﬁrst hospitalization.
Our study is similar to Tiihonen et al. (2006, 2011) study in
that it used an observational follow-up design with all-cause
treatment discontinuation as the principal effectiveness mea-
sure. However, unlike the Finnish study, our study included all
patients with the diagnosis of schizophrenia and other psychotic
disorders in Hungary who had been prescribed a new SGA during
the inclusion period. The observational follow-up design with
the availability of nationwide register database provided a
unique opportunity to investigate the relative effectiveness of
SGAs. We were able to study data from a real-world setting,
using a single database with no limitation regarding the
population selection, and with a large sample size that allowed
for a head-to-head comparison of many of the currently
marketed SGA.
One of the major conclusions from the Finnish studies was
that ‘‘only a minority of patients adhere to their initial
antipsychotic during the ﬁrst 60 days after discharge fromtheir ﬁrst hospitalization for schizophrenia’’ (Tiihonen et al.,
2011). Our ﬁndings based on the full-population of schizo-
phrenia patients in Hungary indicated somewhat longer times
to all-cause discontinuation, but still the median survival
times were less than 120 days for the majority of oral APs.
Overall, our data regarding medication differences are
similar to the Finnish data (Tiihonen et al., 2006, 2011),
supporting the superior efﬁcacy of a depot formulation and
the efﬁcacy rank order of oral olanzapine and risperidone.
The signiﬁcant differences in the time to discontinuation
between the patients treated with oral SGAs or RLAI in this
naturalistic study supports the conclusions of a meta-
analysis that recent challenges of the beneﬁts of depot
formulations over oral formulations of antipsychotics may
be related to the fact, that RCTs are less representative of
real-world patients than naturalistic studies (Kishimoto
et al., 2013). The fact that clozapine did not perform as
well in our as in the Finnish study might be linked to the use
of clozapine after ﬁrst hospitalization in Finland, while in
the entire, more chronic population (mainly in treatment
resistant patients as deﬁned by the summary of the product
characteristics of clozapine) in Hungary.
The present study has limitations. First, the fact that the
last day of treatment cannot be determined precisely by the
register-based database may have introduced an additional
variability into our estimates of time to all-cause disconti-
nuation. The fact that we adopted a uniform criterion for
medication discontinuation (14 days after the last dispensa-
tion) across all oral and depot medications makes it unlikely
that the results of our comparisons were confounded by this
problem. Second, approximately one quarter of the patients
received polypharmacy with another SGA before medication
discontinuation. However, the proportions of polypharmacy
were somewhat lower than those reported in the Inter-
continental Schizophrenia Outpatient Health Outcomes (IC-
SOHO) investigation, an observational study (Dossenbach
et al., 2005), and exhibited only a small variation across
treatments. This makes it unlikely that the use of poly-
pharmacy introduced a bias into our medication compar-
isons. Finally, our study was observational with no ratings of
psychopathology or measures of side effects/tolerability;
and with no random treatment allocation, which may have
introduced selection bias, thereby limiting the external
validity of the results. While we applied propensity score-
based adjustment to counter this problem, future studies
may wish to address this issue further.Role of funding source
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